Donald Smee


Affiliation: Utah State University
Country: USA


  1. request reprint
    Smee D, Wong M, Bailey K, Beadle J, Hostetler K, Sidwell R. Effects of four antiviral substances on lethal vaccinia virus (IHD strain) respiratory infections in mice. Int J Antimicrob Agents. 2004;23:430-7 pubmed
    ..These data indicate the utility of parenteral cidofovir, oral HDP-CDV and oral HOE961 in treating severe respiratory infections caused by this virus. ..
  2. request reprint
    Smee D, Bailey K, Wong M, Wandersee M, Sidwell R. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J Infect Dis. 2004;190:1132-9 pubmed
    ..Topical cidofovir treatment was superior to parenteral treatment. This new animal model may be useful in evaluation of the efficacy of treatment regimens against complications from smallpox vaccination. ..
  3. request reprint
    Smee D, Wandersee M, Checketts M, O Keefe B, Saucedo C, Boyd M, et al. Influenza A (H1N1) virus resistance to cyanovirin-N arises naturally during adaptation to mice and by passage in cell culture in the presence of the inhibitor. Antivir Chem Chemother. 2007;18:317-27 pubmed
    ..The mutations reported here causing resistance to CVN are consistent with its known mode of action. ..
  4. request reprint
    Smee D, Bray M, Huggins J. Intracellular phosphorylation of carbocyclic 3-deazaadenosine, an anti-Ebola virus agent. Antivir Chem Chemother. 2001;12:251-8 pubmed
    ..C-c3ATP may represent a form of C-c3Ado that might contribute to extending its intracellular half life or otherwise exhibit antiviral activity and/or toxicity. ..
  5. request reprint
    Smee D, Bailey K, Wong M, Sidwell R. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir. Antiviral Res. 2000;47:171-7 pubmed
    ..The data suggest the possibility that aerosol delivery of cidofovir to human lungs may be a viable alternative to intravenous dosing...
  6. request reprint
    Smee D, Bailey K, Sidwell R. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir. Antivir Chem Chemother. 2001;12:71-6 pubmed
    ..Although it has been known for many years that the WR strain of vaccinia virus can cause lethal infections by intranasal route, its application to antiviral therapy represents a new model for studying anti-orthopoxvirus agents. ..
  7. Smee D, Sidwell R, Kefauver D, Bray M, Huggins J. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses. Antimicrob Agents Chemother. 2002;46:1329-35 pubmed
    ..Studies will need to be conducted with cidofovir-resistant monkeypox virus in monkeys to further support these hypotheses...
  8. request reprint
    Smee D, Bray M, Huggins J. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro. Antivir Chem Chemother. 2001;12:327-35 pubmed
    ..Biological differences in mode of action and immunosuppressive potential between ribavirin and MPA may account for why the former compound is active against orthopoxvirus infections in animals and the latter inhibitor is not. ..
  9. request reprint
    Smee D, Sidwell R. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003;57:41-52 pubmed

More Information


  1. request reprint
    Smee D, Bailey K, Sidwell R. Comparative effects of cidofovir and cyclic HPMPC on lethal cowpox and vaccinia virus respiratory infections in mice. Chemotherapy. 2003;49:126-31 pubmed
    ..Thus, it was deemed important to directly compare the activities of cidofovir and cyclic HPMPC against poxvirus infections in mouse models...
  2. request reprint
    Smee D, Sidwell R. Anti-cowpox virus activities of certain adenosine analogs, arabinofuranosyl nucleosides, and 2'-fluoro-arabinofuranosyl nucleosides. Nucleosides Nucleotides Nucleic Acids. 2004;23:375-83 pubmed
    ..None of the other compounds, including IDU, prevented death nor delayed the time to death. Cidofovir had the best potential for treating orthopoxvirus infections of those tested...
  3. request reprint
    Smee D, Wandersee M, Bailey K, Wong M, Chu C, Gadthula S, et al. Cell line dependency for antiviral activity and in vivo efficacy of N-methanocarbathymidine against orthopoxvirus infections in mice. Antiviral Res. 2007;73:69-77 pubmed
    ..Cidofovir (100mg/kg/day) protected animals from death in all three infections. ..
  4. Smee D, Gowen B, Wandersee M, Wong M, Skirpstunas R, Baldwin T, et al. Differential pathogenesis of cowpox virus intranasal infections in mice induced by low and high inoculum volumes and effects of cidofovir treatment. Int J Antimicrob Agents. 2008;31:352-9 pubmed publisher
    ..Cidofovir effectively treated both infections and slowed viral replication sufficiently to subdue the exaggerated release of pro-inflammatory mediators...
  5. request reprint
    Smee D, Humphreys D, Hurst B, Barnard D. Antiviral activities and phosphorylation of 5-halo-2'-deoxyuridines and N-methanocarbathymidine in cells infected with vaccinia virus. Antivir Chem Chemother. 2008;19:15-24 pubmed
    ..The antipoxviral activities and phosphorylation of N-methanocarbathymidine ([N]-MCT) and four 5-halo-2'-deoxyuridines, namely 5-fluoro-(FdU), 5-chloro-(CldU), 5-bromo-(BrdU), and 5-iodo-(IdU) derivatives, were explored...
  6. request reprint
    Smee D. Progress in the discovery of compounds inhibiting orthopoxviruses in animal models. Antivir Chem Chemother. 2008;19:115-24 pubmed
    ..Another compound with high activity but requiring parenteral administration is HPMPO-DAPy. Further development of these compounds is warranted...